Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies.
Silverstein
M J
MJ
Keck School of Medicine, University of Southern California, Los Angeles, USA.
Parker
R
R
Grotting
J C
JC
Cote
R J
RJ
Russell
C A
CA
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D001365:Axilla; D001706:Biopsy / Q000295:instrumentation / Q000379:methods; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000175:diagnosis* / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008207:Lymphatic Metastasis; D016462:Mammaplasty / Q000379:methods; D008408:Mastectomy / Q000379:methods / Q000534:rehabilitation; D009364:Neoplasm Recurrence, Local; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen